-
Mashup Score: 6ESMO Congress 2023: Registration - 10 month(s) ago
Registration is now open
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Crossover in a randomized trial can skew the interpretation of the efficacy of a cancer drug. In this Comment, I use examples from clinical trials presented at the 2023 ASCO annual meeting to highlight why ‘allowing’ crossover in randomized trials testing cancer drugs is problematic, and propose that crossovers should either be mandated or prohibited depending on the context.
Source: NatureCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a new Comment, @oncology_bg discusses 'Problematic crossovers in cancer drug trials' using pertinent recent examples presented at #ASCO23: https://t.co/DqPM0oS1ze #medonc #hpeonc https://t.co/Gd9RgBtP0T
-
-
Mashup Score: 2ESMO Congress 2023: Registration - 10 month(s) ago
Registration is now open
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMO23: Join your international colleagues in Madrid to learn about latest practice challenges & controversies in #oncology today. One week left for preferential rates. ⏰ Deadline 19 July. 🔗 https://t.co/0WrxVuHWOR @AndresC27622123 @Silke_Gillessen #CancerResearch #MedOnc https://t.co/jAzOmlvggV
-
-
Mashup Score: 0A critical appraisal of the ATLAS trial of maintenance therapy for multiple myeloma: end points, censoring and equipoise - Nature Reviews Clinical Oncology - 10 month(s) ago
A recent report from the ATLAS trial comparing different maintenance strategies following haematopoeitic stem cell transplantation for multiple myeloma provides an opportunity to explore various themes of critical appraisal, including end points, the equipoise of trial design, and the part censoring can play in the validity of results.
Source: NatureCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In a new article now live online, @ManniMD1 & @TomerMeirson critically appraise the ATLAS trial of maintenance therapy for multiple myeloma, highlighting issues regarding end points, censoring and equipoise: https://t.co/4ky6e8dqsS #hemeonc #medonc #MMSM https://t.co/SKPgBQfZVt
-
-
Mashup Score: 0Clive Peedell (@clivepeedell) on Threads - 10 month(s) ago
Consultant Clinical Oncologist. Politics/medical politics. #NHS campaigner. BTOG and UK SABR Consortium steering committee member. Views are personal. 64 Followers.
Source: ThreadsCategories: Latest Headlines, Oncologists2Tweet-
At some point I would love to delete Twitter and move to #Threads permanently. It’s going to take some transition time, because I use Twitter for #MedEducation purposes. Please follow the trend to move though #Medtwitter #Radonc #Medonc #Lcsm #Pcsm #nhs https://t.co/MqPhedmbn9
-
-
Mashup Score: 0Clive Peedell (@clivepeedell) on Threads - 10 month(s) ago
Consultant Clinical Oncologist. #NHS campaigner. Views are personal. BTOG and UK SABR Consortium steering committee member. 5 Followers.
Source: ThreadsCategories: Latest Headlines, Oncologists2Tweet-
I’m now on #Threads too. Would be good to rebuild a #radonc #medonc and #medtwitter community there and eventually delete my #Twitter account (unless @elonmusk is bought out) https://t.co/MqPhedmbn9
-
-
Mashup Score: 0Radiation dose, schedule and novel systemic targets for radio-immunotherapy combinations - 11 month(s) ago
Abstract. Immunotherapy combinations are being investigated to expand the benefit of immune- checkpoint blockade across many cancer types. Radiation combination
Source: OUP AcademicCategories: Hem/Oncs, Latest HeadlinesTweet-
Field-leading review⚡️#radiation #immunotherapy combos @JNCI_Now from our collaborative #radonc #medonc teams @UPMCHillmanCC @MoffittNews @UChicagoRadonc - great work @KarapetLilit! Field needs focus on dose/fractionation & novel IO! Free-access link: https://t.co/qM5JJTXX1s https://t.co/VLLhfp4tPa
-
-
Mashup Score: 0Changes to Primary Endpoints of ICI Trials Are Not Being Disclosed - 11 month(s) ago
Researchers are changing primary endpoints for trials of immune checkpoint inhibitors without making note of these changes, a review suggests.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Researchers are changing primary endpoints for trials of immune checkpoint inhibitors without making note of these changes, a systematic review suggests. Published in @JAMAOnc. https://t.co/tlyP2xEAaT #MedOnc #CancerResearch
-
-
Mashup Score: 0FDA approves talazoparib with enzalutamide for HRR gene-mutated metast - 11 month(s) ago
FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Yesterday, the FDA approved talazoparib in combination with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer based on rPFS data from the randomized TALAPRO-2 trial: https://t.co/fCw1KAwiGb #PCSM #medonc #uroonc
-
-
Mashup Score: 2ESMO Congress 2023: Registration - 11 month(s) ago
Registration is now open
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMO23: If you don’t want to miss the most prestigious international #oncology platform and benefit from preferential rates, now is the time to register. Best saving by 19 July. 🔗 https://t.co/qydO3H9OJI @AndresC27622123 @Silke_Gillessen #CancerResearch #MedOnc https://t.co/fE1jv8sCCj
-
Just over 24 hours left to register at the best rates for the ESMO Congress 2023. Karin Jordan, Educational Chair, invites you to join around 30,000 professionals to learn about the latest in #oncology ⏰ Deadline 19 July 🔗 https://t.co/LRYjgaAt8c #CancerResearch #MedOnc #ESMO23 https://t.co/yPXPS3LEa0